Conduct your own due diligence and consult a financial adviser before making any investment decisions. While biotechnology (BioTech) is a very large field, its largest impact is in medicine. For a ...

Investors in these stocks should be very aware that early-stage biotech stocks have huge upside but also bust potential, and to invest within your risk tolerance accordingly. Billy Duberstein and ...

The CRISPR biotech is now shelving the autoimmune program and slashing staff in order to focus its resources and its finances on the two lead cancer programs, whose data readouts have been delayed ...

By Deena Beasley (Reuters) -Amgen on Friday announced a $900 million expansion of its Ohio biotech manufacturing facility, becoming the latest in a string of drugmakers pledging to increase U.S ...

Subscribe Login Register Log out My Profile Subscriber Services Search PGe NEWSLETTERS PG STORE ARCHIVES OBITUARIES JOBS PUBLIC NOTICES CLASSIFIEDS EVENTS PETS CONTACT US ADVERTISING CAREER ...

NEW YORK, April 25, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines ...

But today, Kendall has been reborn — as the glittering, glassy heart of America’s biotech industry. For many companies, Kendall Square’s status as a global center of biotechnology firms and ...

The recently announced expansion will add to the roughly 400 jobs already promised in central Ohio by the biotech company and bring its total local investment to $1.4 billion. The expansion is on ...

School of Basic Medical Sciences, Hubei University of Chinese Medicine, Wuhan 430065, China State Key Laboratory of Freshwater Ecology and Biotechnology, Institute of Hydrobiology, Chinese Academy of ...

Commenting on the investment, Shruti Srivastava, investment director at Avaana Capital, said, “Their proprietary insect biotechnology and bioprocessing platform enables the production of ...

Now it has a promising new drug. Jon Pilcher’s spare bedroom in Melbourne’s southern suburbs is the unlikely engine room of a $1.3 billion global biotech. The chief executive of Neuren ...

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech ...